Abbott Laboratories Inc. shed a significant drag on its efforts to pick up market-share in the US cardiac rhythm management market with the Feb.1 FDA approval of MRI-conditional labeling for its pacemakers.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?